Capital Research Global Investors Buys Shares of 421,575 Inhibrx Biosciences, Inc. $INBX

Posted by Brian Himes on Jun 10th, 2026

Capital Research Global Investors bought a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 421,575 shares of the company’s stock, valued at approximately $33,304,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Inhibrx Biosciences by 26.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock valued at $56,000 after acquiring an additional 147 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Inhibrx Biosciences by 1.3% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 22,883 shares of the company’s stock valued at $1,808,000 after acquiring an additional 299 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Inhibrx Biosciences by 71.9% in the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after acquiring an additional 789 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in Inhibrx Biosciences in the fourth quarter valued at approximately $66,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Inhibrx Biosciences in the third quarter valued at approximately $40,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on INBX shares. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research note on Friday, April 24th. Wall Street Zen lowered shares of Inhibrx Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Stifel Nicolaus assumed coverage on shares of Inhibrx Biosciences in a research report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 price target on the stock. Finally, Zacks Research raised shares of Inhibrx Biosciences to a “hold” rating in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Inhibrx Biosciences currently has a consensus rating of “Hold” and an average target price of $150.00.

Check Out Our Latest Stock Report on INBX

Inhibrx Biosciences Trading Down 0.0%

NASDAQ:INBX opened at $89.10 on Wednesday. Inhibrx Biosciences, Inc. has a 12 month low of $13.92 and a 12 month high of $155.29. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -10.62 and a beta of 3.31. The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 12.58. The company’s 50 day moving average is $98.73 and its 200-day moving average is $84.82.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47). Equities analysts anticipate that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current year.

Inhibrx Biosciences Profile

(Free Report)

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.